Kalaris Therapeutics, Inc.
$6.6
▼
-2.44%
2026-04-21 07:44:00
kalaristx.com
NGM: KLRS
Explore Kalaris Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$132.49 M
Current Price
$6.6
52W High / Low
$11.88 / $2.14
Stock P/E
—
Book Value
$3.44
Dividend Yield
—
ROCE
-41.2%
ROE
-3.08%
Face Value
—
EPS
$-2.85
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
20
Beta
—
Debt / Equity
1.84
Current Ratio
12.23
Quick Ratio
12.23
Forward P/E
-4.33
Price / Sales
—
Enterprise Value
$27.91 M
EV / EBITDA
-0.6
EV / Revenue
—
Rating
Strong Buy
Target Price
$20.33
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | AC Immune SA | $2.98 | — | $303.29 M | — | -115.62% | -89.65% | $4 / $1.45 | $0.56 |
| 2. | Generate Biomedicines, Inc. | $12.12 | — | $1.59 B | — | -94.79% | -81.72% | $15.32 / $11 | $-12.24 |
| 3. | Lyell Immunopharma, Inc. | $24.89 | — | $559.6 M | — | -69.37% | -86.98% | $45 / $7.65 | $11.68 |
| 4. | Jupiter Neurosciences, Inc. | $0.46 | — | $15.86 M | — | -73.72% | -7.39% | $3.33 / $0.31 | $0 |
| 5. | Artelo Biosciences, Inc. | $4.53 | — | $3.96 M | — | 917.46% | -16.25% | $85.8 / $2.96 | $-1.89 |
| 6. | Mirum Pharmaceuticals, Inc. | $95.71 | — | $5.78 B | — | -3.47% | -8.65% | $109.28 / $38.22 | $6.06 |
| 7. | PTC Therapeutics, Inc. | $72.32 | 8.72 | $5.95 B | — | 44.37% | -104.75% | $87.5 / $35.95 | $-2.52 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -10.8 M | -12.74 M | -12.26 M | -10.35 M | -7.13 M | — |
| Net Profit | -10 M | -11.89 M | -11.35 M | -10.2 M | -22.03 M | — |
| EPS in Rs | -0.44 | -0.52 | -0.5 | -0.44 | -0.96 | -28.16 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -46.15 M | -51.73 M | -13.46 M | -14.01 M |
| Net Profit | -43.44 M | -69.17 M | -14.7 M | -15.48 M |
| EPS in Rs | -1.89 | -3.02 | -0.64 | -0.68 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 121.74 M | 6.16 M | 3.33 M | 3.9 M |
| Total Liabilities | 42.92 M | 102.78 M | 48.35 M | 34.17 M |
| Equity | 78.81 M | -96.62 M | -45.02 M | -30.27 M |
| Current Assets | 118.81 M | 2.61 M | 3.33 M | 3.9 M |
| Current Liabilities | 9.71 M | 24.7 M | 3.94 M | 5.69 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -38.37 M | -20.67 M | -14.13 M | -9.78 M |
| Investing CF | -19.72 M | 0 M | — | — |
| Financing CF | 155.01 M | 19.14 M | 14.24 M | 12.78 M |
| Free CF | -38.57 M | -20.67 M | -14.13 M | -9.78 M |
| Capex | -0.2 M | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 37.2% | -370.56% | 5.08% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-01-16 | 1:0.0434783 |